Review article · 2024 · Open access
Efficacy of Janus Kinase Inhibitors (JAK) in Combination with Methotrexate for Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Scholars Bulletin, 10(07), 174–185 · Published 22 August 2024 · DOI 10.36348/sb.2024.v10i07.002
In brief
“Efficacy of Janus Kinase Inhibitors (JAK) in Combination with Methotrexate for Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis” is a 2024 review article by Nashwa Essam Dyab and 3 co-authors, published in Scholars Bulletin. OpenAlex counts 1 citations as of 19 November 2026. It is open access: the full text is free to read at Scholars Bulletin.
- Citations
- 1
- Most cited in
- 2024 (1)
- Field-weighted impact
- 0.06
- References
- 38
- Authors
- 4
Abstract
Background: Rheumatoid Arthritis is a major public health concern, affecting 0.46% of general population. Janus kinase inhibitors (JAK) emerged as new biological drug for RA management. However, there is limited literature on effectiveness and safety of JAKi in combination therapy for RA management. We aimed to perform a meta-analysis to compare the efficacy and safety of JAKi in combination therapy with MTX as compared to MTX alone among RA patients. Methods: The recent meta-analysis of randomized controlled trials (RCT) have been conducted in accordance with Preferred Reporting Items for Systematic Review and Meta-analysis Protocols to fulfil research aims. Three electronic databases named as PubMed, Cochrane library and clinical trials.gov were used for research articles extraction. Primary outcomes were American College of Rheumatology criteria for 20% improvement (ACR20 response), Disease Activity Score in 28 joints (DAS28), Health Assessment Questionnaire disability index (HAQ-DI), and adverse events (TEAE). The Cochrane Risk of Bias tool was used to evaluate the quality of each included randomized clinical trials. The pooled analysis was conducted by using RevMan (Review Manager) software version 5.4. Results: About 407 research articles were extracted from electronic databases and only 9 RCT’s met the inclusion criteria. About 9 RCT’s and 6853 RA patients met the inclusion criteria with 5040 patients receiving JAKi plus MTX in combination and 1813 patients receiving MTX in monotherapy. The pooled analysis showed that ACR20 have significantly improved among group receiving combination therapy as compared to MTX alone (Placebo) [OR: 2.44 (1.35 to 4.40) Cl: 95%] while TEAE numbers have favored the MTX alone as compared to group receiving combination therapy [RR: 1.29 (0.89 to 1.87) Cl: 95%], because number of adverse events were higher among treatment group. Moreover, the mean difference showed that HAQ DI [Mean difference: -0.53 (0.94 to -0.11) Cl: 95%], DAS28 [Mean difference: -1.85 (-2.83 to -0.86) Cl: 95%] have significantly decreased among group receiving combination therapy as compared to MTX alone (Placebo). Conclusion: Overall, the findings of recent meta-analysis revealed that JAKi in combination therapy with MTX improved the ACR20 responses, Clinical Disease Activity Index (CDAI), and mean creatinine levels, as compared to MTX alone among RA patients. However, the frequency of adverse events by JAKi plus MTX was higher as compared to MTX alone that compromised the safety profile of combination therapy.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Dyab, N. E., Alhurh, A. A., Knifaty, A. M., & Mahdy, E. W. (2024). Efficacy of Janus Kinase Inhibitors (JAK) in Combination with Methotrexate for Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Scholars Bulletin, 10(07), 174–185. https://doi.org/10.36348/sb.2024.v10i07.002
MLA 9
Dyab, Nashwa Essam, et al. “Efficacy of Janus Kinase Inhibitors (JAK) in Combination with Methotrexate for Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.” Scholars Bulletin, vol. 10, no. 07, 2024, pp. 174–185. https://doi.org/10.36348/sb.2024.v10i07.002.
Chicago
Dyab, Nashwa Essam, Areej Alkhalil Alhurh, Aya Mudar Knifaty, and Eman Wagih Mahdy. 2024. “Efficacy of Janus Kinase Inhibitors (JAK) in Combination with Methotrexate for Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.” Scholars Bulletin 10 (07): 174–185. https://doi.org/10.36348/sb.2024.v10i07.002.
Harvard
Dyab, N. E. et al. (2024) ‘Efficacy of Janus Kinase Inhibitors (JAK) in Combination with Methotrexate for Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis’, Scholars Bulletin, 10(07), pp. 174–185. doi:10.36348/sb.2024.v10i07.002.
IEEE
N. E. Dyab, A. A. Alhurh, A. M. Knifaty, and E. W. Mahdy, “Efficacy of Janus Kinase Inhibitors (JAK) in Combination with Methotrexate for Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis,” Scholars Bulletin, vol. 10, no. 07, pp. 174–185, 2024, doi: 10.36348/sb.2024.v10i07.002.
BibTeX
@article{dyab2024efficacy,
title = {{Efficacy of Janus Kinase Inhibitors (JAK) in Combination with Methotrexate for Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis}},
author = {Dyab, Nashwa Essam and Alhurh, Areej Alkhalil and Knifaty, Aya Mudar and Mahdy, Eman Wagih},
journal = {Scholars Bulletin},
year = {2024},
volume = {10},
number = {07},
pages = {174--185},
doi = {10.36348/sb.2024.v10i07.002},
url = {https://doi.org/10.36348/sb.2024.v10i07.002}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Topic and keywords
Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- rheumatoid arthritis
- JAK inhibitors
- methotrexate
- combination therapy
- monotherapy
- ACR20 response
- DAS28
- HAQ-DI
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Dyab, N. E., Alhurh, A. A., Knifaty, A. M., & Mahdy, E. W. (2024). Efficacy of Janus Kinase Inhibitors (JAK) in Combination with Methotrexate for Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. Scholars Bulletin, 10(07), 174–185. https://doi.org/10.36348/sb.2024.v10i07.002
How many times has this paper been cited?
1 times, according to OpenAlex on 19 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at Scholars Bulletin: sign in and open the PDF from this page.
Who wrote this paper?
Nashwa Essam Dyab, Areej Alkhalil Alhurh, Aya Mudar Knifaty, Eman Wagih Mahdy.
What is the DOI of this paper?
10.36348/sb.2024.v10i07.002, permanently at https://doi.org/10.36348/sb.2024.v10i07.002. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 19 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.